GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Total Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Liabilities | ₹14,925 Cr | ₹13,309 Cr | ₹17,566 Cr | ₹15,397 Cr | ₹14,069 Cr |
What is the latest Total Liabilities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Total Liabilities |
|---|---|
| Mar2025 | ₹14,925 Cr |
| Mar2024 | ₹13,309 Cr |
| Mar2023 | ₹17,566 Cr |
| Mar2022 | ₹15,397 Cr |
| Mar2021 | ₹14,069 Cr |
How is Total Liabilities of GLENMARK PHARMACEUTICALS Trending?
| Years | Total Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹14,925 Cr | 12.15 | |
| Mar2024 | ₹13,309 Cr | -24.23 | |
| Mar2023 | ₹17,566 Cr | 14.08 | |
| Mar2022 | ₹15,397 Cr | 9.44 | |
| Mar2021 | ₹14,069 Cr | - | |
Compare Total Liabilities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹58,649.6 Cr | 0.6% | 7.2% | 30.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹422,631.0 Cr | 1.9% | -0.8% | -3.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹175,111.0 Cr | 3.2% | 4.8% | 12.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹136,228.0 Cr | 6.3% | 8.9% | 15.8% | Stock Analytics | |
| CIPLA | ₹117,983.0 Cr | -3.3% | -2% | -1.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,782.0 Cr | -3.8% | -3.1% | -8% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 0.6% |
7.2% |
30.3% |
| SENSEX | -1.2% |
-1.1% |
6.3% |
You may also like the below Video Courses